Micromet

Shares of Micromet (NASDAQ: MITI), a biopharmaceutical company based in Rockville, Maryland, closed up 8.7% Friday. In a press release, the company said research suggests that its new antibody agent called blinatumomab, may be a useful weapon against acute lymphoblastic leukemia (ALL)....

RBC Capital has upgraded Micromet (NASDAQ: MITI) from Sector Perform to Outperform and has established an $8 price target.

Piper Jaffray has released a report that focuses on next-gen antibody companies. “Over the past several years, we have seen significant consolidation in the biotherapeutic space,” Piper Jaffray writes. “We expect this trend to continue due to the scarcity of antibody technologies and the longer...

Piper Jaffray reiterates its Overweight rating on Micromet (NASDAQ: MITI) based on the advancement and expansion of MITI's BiTE antibody pipeline. In a note to clients, Piper Jaffray writes, "Following a $70.5 million offering, Micromet now holds pro forma cash of $235 million. The cash should last...